Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 h ago

Vor Biopharma Inc.: Venrock Healthcare Capital Partners III, L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Venrock Healthcare Capital Partners III, L.P. amended its Schedule 13G stake filing for Vor Biopharma Inc., disclosing the change in a filing with the SEC under accession number 0001738048-26-000098. The amendment updates the venture firm's reported ownership position in the clinical-stage biotech, though the filing summary did not specify the revised share count or percentage. Schedule 13G amendments are typically filed when a passive investor's stake crosses or adjusts around the 5% reporting threshold, making the disclosure a signal of Venrock's current exposure to the company. Investors will watch for the detailed filing to confirm the exact size and direction of the position change, and for any subsequent 13G or 13D filings that could indicate a shift in intent. Vor Biopharma, which develops engineered hematopoietic stem cell therapies for blood cancers, remains closely held by institutional backers, so changes among top holders can matter for governance and float.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Vor Biopharma Inc., Venrock Healthcare Capital Partners III, L.P.